CEFTRIAXONE INJECTION, USP SOLUTION

País: Canadà

Idioma: anglès

Font: Health Canada

ingredients actius:

CEFTRIAXONE (CEFTRIAXONE SODIUM)

Disponible des:

BAXTER CORPORATION

Codi ATC:

J01DD04

Designació comuna internacional (DCI):

CEFTRIAXONE

Dosis:

1000MG

formulario farmacéutico:

SOLUTION

Composición:

CEFTRIAXONE (CEFTRIAXONE SODIUM) 1000MG

Vía de administración:

INTRAVENOUS

Unidades en paquete:

15G/50G

tipo de receta:

Prescription

Área terapéutica:

THIRD GENERATION CEPHALOSPORINS

Resumen del producto:

Active ingredient group (AIG) number: 0117292011; AHFS:

Estat d'Autorització:

APPROVED

Data d'autorització:

2020-06-02

Fitxa tècnica

PRODUCT MONOGRAPH
Including Patient Medication Information
PR
CEFTRIAXONE INJECTION, USP
CEFTRIAXONE (AS CEFTRIAXONE SODIUM USP)
1000 MG / 50 ML AND 2000 MG / 50 ML IN SINGLE DOSE GALAXY CONTAINERS
READY-TO-USE
STERILE SOLUTION (FROZEN)
ANTIBIOTIC
BAXTER CORPORATION
7125 Mississauga Road
Mississauga, Ontario
L5N 0C2
CONTROL #: 215096
Date of Preparation: May 28, 2020
BAXTER AND GALAXY ARE REGISTERED TRADEMARKS OF BAXTER
INTERNATIONAL INC.
Ceftriaxone Injection, USP
Page 2 of 52
TABLE OF CONTENTS
HEALTH PROFESSIONAL INFORMATION
.........................................................................
3
ACTION
......................................................................................................................................
3
INDICATIONS AND CLINICAL USES
...................................................................................
3
CONTRAINDICATIONS
...........................................................................................................
4
WARNINGS
...............................................................................................................................
4
PRECAUTIONS
.........................................................................................................................
7
ADVERSE REACTIONS
...........................................................................................................
8
SYMPTOMS AND TREATMENT OF OVERDOSAGE
........................................................ 10
DOSAGE AND ADMINISTRATION
.....................................................................................
10
ADMINISTRATION
................................................................................................................
11
SPECIAL HANDLING INSTRUCTIONS
...............................................................................
12
PHARMACEUTICAL INFORMATION
.................................................................................
13
DRUG SUBSTANCE
.................................................................